Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Neutral

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Neutral

Analyst Rating

Buy

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Emergent Biosolutions, Inc. (EBS)

Pharmaceutical Preparations

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

400 PROFESSIONAL DR, SUITE 400
GAITHERSBURG, MD

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

11/15/2006

Market Cap

556,048,366

Shares Outstanding

51,880,000

Weighted SO

51,884,398

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

ZTS --.--%

PETQ --.--%

BHC --.--%

NBIX --.--%

AKAN --.--%

LFCR --.--%

PBH --.--%

ITCI --.--%

IZQVF --.--%

Beta

1.6190

Last Div

0.0000

Range

1.42-15.1

Chg

1.8500

Avg Vol

2708774

Mkt Cap

556048366

Exch

NYSE

Country

US

Phone

240 631 3200

DCF Diff

28.7093

DCF

-13.9393

Div Yield

0.0000

P/S

0.5045

EV Multiple

-16.3096

P/FV

1.4311

Div Yield %

0.0000

P/E

-0.9378

PEG

-0.3119

Payout

0.0000

Current Ratio

1.0562

Quick Ratio

0.5438

Cash Ratio

0.1146

DSO

65.0059

DIO

136.5310

Op Cycle

201.5369

DPO

41.2388

CCC

160.2981

Gross Margin

0.2299

Op Margin

-0.3659

Pretax Margin

-0.5245

Net Margin

-0.5348

Eff Tax Rate

-0.0479

ROA

-0.3895

ROE

-0.9839

ROCE

-0.4512

NI/EBT

1.0197

EBT/EBIT

1.4334

EBIT/Rev

-0.3659

Debt Ratio

0.5717

D/E

2.2400

LT Debt/Cap

0.5364

Total Debt/Cap

0.6914

Int Coverage

-9.4671

CF/Debt

0.0890

Equity Multi

3.9179

Rec Turnover

5.6149

Pay Turnover

8.8509

Inv Turnover

2.6734

FA Turnover

3.4455

Asset Turnover

0.7282

OCF/Share

1.4639

FCF/Share

0.7148

Cash/Share

1.3498

OCF/Sales

0.0699

FCF/OCF

0.4883

CF Coverage

0.0890

ST Coverage

0.1841

CapEx Coverage

1.9543

Div&CapEx Cov

1.9543

P/BV

1.4311

P/B

1.4311

P/S

0.5045

P/E

-0.9378

P/FCF

14.7885

P/OCF

7.1796

P/CF

7.1796

PEG

-0.3119

P/S

0.5045

EV Multiple

-16.3096

P/FV

1.4311

DPS

0.0000

Latest Headlines (EST)

The Motley Fool Dec 30, 22:26 Why Emergent BioSolutions Stock Blasted Higher Today The Motley Fool Dec 03, 23:47 Why Emergent BioSciences Stock Plummeted Today GlobeNewswire Inc. Aug 29, 22:53 Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions GlobeNewswire Inc. Aug 19, 21:10 Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa GlobeNewswire Inc. Jan 09, 07:30 Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024 GlobeNewswire Inc. Nov 24, 07:30 Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing The Motley Fool Nov 08, 23:00 Emergent BioSolutions (EBS) Q3 2023 Earnings Call Transcript The Motley Fool Nov 08, 23:00 Emergent BioSolutions (EBS) Q3 2023 Earnings Call Transcript The Motley Fool Nov 08, 23:00 Emergent BioSolutions (EBS) Q3 2023 Earnings Call Transcript GlobeNewswire Inc. Nov 08, 17:38 Emergent BioSolutions Reports Third Quarter 2023 Financial Results GlobeNewswire Inc. Oct 30, 16:45 UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023

Revenue Product Segmentation